Author:
Cortés Javier,Saura Cristina,Bellet Meritxell,Muñoz-Couselo Eva,Ramírez-Merino Natalia,Calvo Virginia,Pérez Jose,Vidal María
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
2. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
3. Untch, M. et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann. Oncol. 19, 1090–1096 (2008).
4. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
5. Pusztai, L. et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin. Cancer Res. 9, 2406–2415 (2003).